Common Contracts
2 similar Exclusive Option Agreement contracts by Pieris Pharmaceuticals, Inc.
CONFIDENTIAL TREATMENT REQUESTED EXCLUSIVE OPTION AGREEMENTExclusive Option Agreement • April 26th, 2018 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
This Exclusive Option Agreement (the “Agreement”) is entered into by and between Pieris Pharmaceuticals Inc., a Nevada corporation with an address of 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a German company with an address of Lise-Meitner-Strasse 30 85354 Freising, Germany (collectively, “Pieris”), and ASKA Pharmaceutical Co., Ltd., a Japanese corporation with an address of 2-5-1 Shibaura, Minato-ku, Tokyo, Japan 108-8532 (“ASKA”), is effective on February 27, 2017 (the “Effective Date”). Pieris and ASKA are also individually referred to herein as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED EXCLUSIVE OPTION AGREEMENTExclusive Option Agreement • May 15th, 2017 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Exclusive Option Agreement (the “Agreement”) is entered into by and between Pieris Pharmaceuticals Inc., a Nevada corporation with an address of 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a German company with an address of Lise-Meitner-Strasse 30 85354 Freising, Germany (collectively, “Pieris”), and ASKA Pharmaceutical Co., Ltd., a Japanese corporation with an address of 2-5-1 Shibaura, Minato-ku, Tokyo, Japan 108-8532 (“ASKA”), is effective on February 27, 2017 (the “Effective Date”). Pieris and ASKA are also individually referred to herein as a “Party” and collectively as the “Parties”.
